CANSINO BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.04 CNY | +0.74% |
|
-2.33% | -30.17% |
| 04-29 | CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
| Sales 2024 * | 860M 119M 9.39B | Sales 2025 * | 1.21B 168M 13.23B | Capitalization | 8.59B 1.19B 93.73B |
|---|---|---|---|---|---|
| Net income 2024 * | -286M -39.6M -3.12B | Net income 2025 * | -5M -692K -54.54M | EV / Sales 2024 * | 9.34 x |
| Net cash position 2024 * | 558M 77.28M 6.09B | Net cash position 2025 * | 538M 74.53M 5.87B | EV / Sales 2025 * | 6.64 x |
| P/E ratio 2024 * |
-16.3
x | P/E ratio 2025 * |
-329
x | Employees | 1,494 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.3% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.74% | ||
| 1 week | -2.33% | ||
| Current month | +1.88% | ||
| 1 month | +11.32% | ||
| 3 months | -4.50% | ||
| 6 months | -37.53% | ||
| Current year | -30.17% |
1 week
51.08
54.49
1 month
45.3755.66
Current year
44.0274.79
1 year
44.02101.87
3 years
44.02798.00
5 years
44.02798.00
10 years
44.02798.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Hua Mao
FOU | Founder | 62 | 12/01/09 |
Tao Zhu
FOU | Founder | 51 | 12/01/09 |
Xue Feng Yu
CEO | Chief Executive Officer | 60 | 12/01/09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wing Yu Leung
BRD | Director/Board Member | 53 | 31/08/15 |
Shou Bai Chao
COO | Chief Operating Officer | 61 | 30/04/18 |
Dong Xu Qiu
FOU | Founder | 64 | 12/01/09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.31% | 1 M€ | -10.73% | - | |
| 0.03% | 3 M€ | +10.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 52.04 | +0.74% | 909,508 |
| 16/05/24 | 51.66 | -0.27% | 1,010,395 |
| 15/05/24 | 51.8 | -2.06% | 773,290 |
| 14/05/24 | 52.89 | +1.36% | 1,106,618 |
| 13/05/24 | 52.18 | -2.06% | 1,402,321 |
End-of-day quote Shanghai S.E., May 16, 2024
More quotes
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Sector
Pharmaceuticals
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19.9
CNY
Average target price
25.66
CNY
Spread / Average Target
+28.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B |
- Stock Market
- Equities
- 6185 Stock
- 688185 Stock
